Yubin Kang, MD
Duke Health · Duke University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yubin Kang, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:13 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06822972 · HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMDuke University · recruiting · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory · principal investigator
- Ph1/Ph2NCT02757326 · ABC294640 (Opaganib) in Refractory / Relapsed Multiple MyelomaRedHill Biopharma Limited · terminated · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Clinical Trial of ABC294640 in Patients with Refractory Multiple MyelomaR44CA199767 · NCI · APOGEE BIOTECHNOLOGY CORPORATION · PI Charles D Smith · fiscal years 2015 to 2017Named on NCT02757326
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in multiple myeloma.